In the field of immune checkpoint research, the clinical value of CTLA-4 and PD-1 has been confirmed, but their limited efficacy has driven the exploration of next-generation co-inhibitory receptors such as Lag-3 and TIMD3. TIMD3 (T-cell immunoglobulin-3, also known as CD366), with its unique expression pattern and functional mechanisms, has emerged as a core target in immune regulation research. This article systematically analyzes the molecular characteristics, ligand network, and biological functions of TIMD3, revealing its significant value in disease regulation.
TIMD3 belongs to the Tim gene family and was first identified in the early 21st century. Human TIMD3 is homologous to the mouse Havcr2 gene. Its molecular structure includes an extracellular immunoglobulin V region (IgV), a mucin-like domain, a transmembrane region, and intracellular tyrosine phosphorylation sites. The IgV region serves as the core ligand-binding domain, while the intracellular segment participates in signal transduction through phosphorylation.
TIMD3 expression exhibits distinct cell-type specificity and activation dependence:
Adaptive immune cells: It is primarily expressed in IFN-γ-secreting Th1 and Tc1 cells, serving as a hallmark of type 1 immune responses. In chronic infections or tumor microenvironments, exhausted CD8⁺ T cells highly express TIMD3, directly correlating with functional impairment. A subset of Treg cells also express TIMD3, with levels associated with their suppressive function.
Innate immune cells: TIMD3 is expressed in dendritic cells (DCs), NK cells, and monocytes, suggesting its role in cross-regulation between innate and adaptive immunity.
The functional diversity of TIMD3 stems from its complex ligand interactions. Major identified ligands include galectin-9, phosphatidylserine (PtdSer), HMGB1, and Ceacam-1, each mediating distinct signaling pathways.
Galectin-9 was the first confirmed ligand of TIMD3, and their binding triggers a strong negative regulatory signal. In Th1 cells, this interaction induces apoptosis, limiting the overactivation of type 1 immune responses. Animal studies show that activation of the galectin-9-TIMD3 pathway reduces inflammatory damage in experimental autoimmune encephalomyelitis (EAE) models, while blocking this pathway exacerbates the disease, confirming its central role in regulating autoimmunity.
PtdSer, a phospholipid molecule on the surface of apoptotic cells, binds to the IgV region of TIMD3 but with lower affinity compared to Tim-1 and Tim-4 in the Tim family. This interaction primarily participates in DC-mediated phagocytosis of apoptotic cells and antigen cross-presentation. In DCs, it may influence the initiation of adaptive immunity by regulating antigen processing.
High-mobility group box 1 (HMGB1), a damage-associated molecule released by necrotic cells, activates receptors like TLR4 to trigger inflammation. TIMD3 binding to HMGB1 competitively inhibits its interaction with TLR4, downregulating pro-inflammatory cytokines (e.g., IL-1β, TNF-α) and limiting excessive inflammation during infections or tissue damage.
Carcinoembryonic antigen-related cell adhesion molecule 1 (Ceacam-1) is a novel ligand of TIMD3, functioning through cis (on the same cell) and trans (intercellular) interactions: cis binding stabilizes TIMD3 expression on the cell surface, while trans binding enhances co-inhibitory signaling. Studies confirm that Ceacam-1 deficiency significantly impairs TIMD3’s negative regulatory function, indicating that their complex is critical for functional exertion.
Through ligand interactions, TIMD3 plays multiple roles in immune homeostasis, infection control, tumor escape, and autoimmune diseases.
TIMD3’s core function is inhibiting Th1 and Tc1 cells. In chronic infections or autoimmune diseases, it limits effector T-cell proliferation and cytokine secretion via galectin-9-mediated apoptotic signals, preventing tissue damage. For example, TIMD3-deficient mice exhibit more severe EAE symptoms, while exogenous TIMD3-Ig fusion proteins reduce inflammation, confirming its role in suppressing autoimmunity.
In tumors or chronic viral infections, persistent antigen stimulation induces T-cell "exhaustion." TIMD3 is a hallmark molecule of exhausted CD8⁺ T cells, with expression levels positively correlating with functional impairment. Blocking TIMD3 partially restores exhausted T-cell activity, and combined with PD-1 blockade, it more effectively enhances anti-tumor or anti-viral immunity.
TIMD3 expression in DCs and NK cells allows it to regulate innate immunity: DCs enhance phagocytosis and antigen presentation via TIMD3, while NK cells may inhibit cytotoxicity through HMGB1 interaction. Additionally, TIMD3⁺ Treg cells accumulate in tumor microenvironments, potentially exacerbating immune suppression and promoting tumor escape.
TIMD3’s unique functions make it a potential target for tumors, autoimmune diseases, and other conditions, with multiple clinical trials exploring its applications.
In tumors, TIMD3 and PD-1 are often co-expressed on exhausted T cells, limiting the efficacy of single-agent blockade. Preclinical studies show that combining anti-TIMD3 and anti-PD-1 significantly enhances T-cell anti-tumor activity and reduces tumor burden. Clinical trials on melanoma and non-small cell lung cancer have preliminarily confirmed the safety and efficacy of combination therapy, offering new approaches to overcome drug resistance.
In autoimmune diseases, abnormal TIMD3 expression or function may disrupt immune tolerance. For instance, reduced proportions of TIMD3⁺ Th1 cells in the peripheral blood of multiple sclerosis patients correlate with disease activity. Enhancing TIMD3 signaling (e.g., via agonists) may restore tolerance and reduce inflammation, though related research is still in early stages.
The multi-ligand nature of TIMD3 poses therapeutic challenges: different ligands may exert antagonistic functions (e.g., galectin-9-induced apoptosis vs. Ceacam-1-mediated co-inhibition), making specific regulation difficult. Additionally, widespread expression in normal tissues may increase off-target effects, requiring the development of cell-type-selective strategies.
As a key node in the immune regulatory network, TIMD3 participates in multiple physiological and pathological processes through diverse ligand interactions. In-depth exploration of its mechanisms, especially synergies with other co-inhibitory receptors, will inform precise combination therapies. With advancing research, TIMD3 is poised to become a crucial new target in immunotherapy.
Business license (three certificates in one) 